118 results about "Mixed cell" patented technology

Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

A unitary apparatus for isolating cells from adipose tissue including a lipid separation processor with a dispersing head equipped with a plurality of ports and a digestion chamber for dissociation of the constituent cells disposed in adipose tissue. The lipid separating apparatus is useful for the separation of lipids and adipocytes from a mixed cell population. A cell seeding chamber may be attached to the cell isolation apparatus. The components of the apparatus may be packaged in modular kit form.

The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.

It is intended to provide a pluripotent cell having the following properties: (1) being contained in a mixed-cell type population obtained by enzymatic treatment of the tissue collected from an animal; (2) being contained in a sedimented cell population obtained by centrifugating the mixed-cell type population of the property (1); (3) selectively proliferating by culturing in a medium containing 2% (v/v) or lower serum and 1 to 100 ng/ml of fibroblast growth factor-2; and (4) being differentiated into cells having the characteristics of adipocytes, osteoblasts, chondrocytes, tendon cells, myocardial cells, myoblasts, neurocytes or vascular endothelial cells by adjusting the culture condition; cells having differentiated from the above cell; and a method of conveniently obtaining the pluripotent cell in a large amount.

The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of a organisms to antimicrobial agents.

The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of a organisms to antimicrobial agents.

Methods and systems are provided for massively parallel genetic analysis of single cells in emulsions or droplets. A biological sample is divided into subsamples of single cells or cell supbopulations, and a fusion complex is formed by molecular linkage and amplification techniques. Methods, apparatuses, and systems are provided for high-throughput, massively parallel analysis of the subsamples. These methods integrate molecular, algorithmic, and engineering approaches. They have broad and useful application in a number of biological and medical fields, including immunology, noninvasive prenatal diagnosis, and noninvasive cancer diagnosis.

The present invention comprises an implantable device that provides artificial tissues for repair, augmentation and reconstructive surgery which have mechanical properties comparable to the natural tissues that they supplement or replace. Such devices can be produced by a tissue engineering method comprising seeding a polymer matrix with a first cell type and a second cell type and culturing the seeded matrix under conditions suitable for cell growth or maintenance, whereby a tissue comprising a mixed cell population containing both the first and second cell types is produced. The tissue produced by this method contains a mixed population in which the two cell types are intimately associated without apparent stratification and has mechanical properties which are intermediate between similarly produced tissues containing either one of the two cell types. This invention is particularly useful in forming implantable structural members.

One of the major hurdles of cellular therapies for the treatment of liver failure is the low availability of functional human hepatocytes. Although embryonic stem (ES) cells represent a potential cell source for therapy, current methods for differentiation result in mixed cell populations or low yields of the cells of interest. The present invention provides for a rapid, direct differentiation method that yields a homogeneous population of endoderm-like cells with 95% purity. In one embodiment, mouse ES cells cultured on top of collagen-sandwiched hepatocytes differentiate and proliferate into a uniform and homogeneous cell population of endoderm-like cells. The endoderm-like cell population was positive for Foxa2, Sox17 and AFP, and could further differentiate into hepatocyte-like cells that demonstrate hepatic morphology, functionality, and gene and protein expression. Incorporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby underscoring the therapeutic potential of these cells.

The invention belongs to the field of biological and medical detection, and relates to a system for separating CTCs (circulating tumor cells) in a blood sample from a mixed cell group in high purity. The separation system for the CTCs comprises a sample preparation module, a sample injection module, a first micro-fluidic chip, a release module and a collection module, wherein the sample preparation module is used for processing blood into a detection sample; the sample injection module is used for injecting the detection sample into the first micro-fluidic chip; the first micro-fluidic chip is used for extracting the CTCs in the detection sample; the release module is used for separating the CTCs from the first micro-fluidic chip and obtaining a collection sample; and the collection module is used for collecting the collection sample. According to the technical scheme, compared with the prior art, the separation system for the CTCs is simple, easy to implement, lower in cost, simple to operate and high in automation degree.

The present invention provides: a method for producing mixed cells comprising cardiomyocytes, endothelial cells and mural cells from induced pluripotent stem cells, the method comprising (a) a step of producing cardiomyocytes from induced pluripotent stem cells and (b) a step of culturing the cardiomyocytes in the presence of VEGF; and a therapeutic agent for heart diseases, comprising the mixed cells produced by the method.

The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.

The invention discloses a method for jointly preparing CAR-NK (chimeric antigen receptor-natural killer) cells and CAR-NKT (natural killer T) cells. The method includes steps of 1), adding peripheral blood mononuclear cells into cell culture media, pre-activating NK cells and NKT cells in the peripheral blood mononuclear cells and selectively activating and amplifying the NK cells and the NKT cells in an in-vitro manner; 2), transducing mixed cells obtained at the step 1) by the aid of lentiviral vectors with gene sequences of chimeric antigen receptors. The method has the advantages that the CAR-NK cells and the CAR-NKT cells can be prepared from NKs and NKTs of healthy donors in a standardized and batched manner; the purity of the NK cells and the NKT cells can respectively reach 60% and 30% at least without purification, and accordingly preliminary purification can be omitted; the in-vivo activation and amplification degrees and the in-vivo existence time of the CAR-NK cells and the CAR-NKT cells which are jointly prepared by the aid of the method can be controlled by means of clinical medication.

The invention belongs to the field of biological and medical detection and relates to equipment, a system and a method for separating CTCs (circulating tumor cells) in a blood sample from mixed cell groups with high purity. The equipment and system for separating the CTCs comprise, but not limited, a control module, a sample injection module, a separation module and a collection module, wherein the control module is used for setting equipment operation parameters including diluents volume, reaction time, sample injection speed, cleaning parameter and the like; the sample injection module adopts a multi-way valve module and a peristaltic pump module and is used for automatically diluting detected samples and starting multi-channel synchronous separation of the samples; the separation module comprises a magnet module and a separator module, the magnet module is used for separating and adsorbing magnetic particle immunolabeled blood leukocytes, and the separator module is used for enriching and separating CTCs from multiple cell groups; the collection module is used for collecting a separated CTC suspension. The invention provides the equipment and the system for separating the CTCs as well as the method for separating and identifying the CTCs.

A memory system, system including the memory system and method of reducing memory system power consumption. The memory system includes multiple memory units allocable to one of a number of processor units, e.g., processors or processor cores. A memory controller receives requests for memory from the processor units and allocates sufficient space from the memory to each requesting processor unit. Allocated memory can include some Single Level per Cell (SLC) memory units storing a single bit per cell and other memory units storing more than one bit per cell. Thus, two processor units may be assigned identical memory space, while half, or fewer, than the number of cells of one are assigned to the other.

The teaching provides a method for selectively lysing sperm cells in a mixed cell sample, particularly in the field of forensic sciences. Reagents and kits for carrying out the methods are also provided.

The invention relates to a skin renewal method. According to the skin renewal method, hair follicle stem cells are used as seed cells and silica gel dressing is used as a new cell transplantation carrier. The skin renewal method comprises the following steps: 1) cultivating and amplifying hair follicle stem cells; 2) cultivating dermal cells; 3) mixing the hair follicle stem cells cultivated and amplified in the step 1) and the dermal cells cultivated in the step 2); 4) dropwise adding mixed cells obtained in the step 3) into silica gel dressing for incubation; and 5) transplanting the cells and the silica gel dressing used in the step 4) to a part required to be subjected to skin renewal. The method provided by the invention not only can renew functional skin in the treatment of large-area skin injuries, but also can provide a simple validation method for the multipotency test on hair follicle stem cells in scientific research activities.

The invention particularly relates to a hybrid cell type identification method based on fine granularity identification, comprising the following steps: a fine granularity identification convolutionalneural network model and a cell image database are established in advance; the cell image database comprises a hybrid cell image; the hybrid cell image is an image including a plurality of types of cells; the hybrid cell type identification method comprises the following steps of: 1, collecting mixed cell images; 2, inputting the mixed cell image into a fine-grained recognition convolution neuralnetwork model to obtain a cell type thermogram; 3, performing threshold that mixed cell image to obtain a binary image of the cell region; 4, combined with binary image of cell region and thermogramof cell species, the cell species identification results being obtained. The invention accurately identifies cell species according to the specificity of cell morphological characteristics, and avoidsthe shortcomings of the traditional cell species identification method that takes a long time and the process is tedious. The model can learn the morphological characteristics of fine-grained cells and identify cell types through texture information, which has high recognition accuracy and robustness.

The invention discloses a method for jointly preparing CAR-VGamma9VDelta2T cells and CAR-NKT cells, comprising the steps of 1) adding peripheral blood mononuclear cells to a cell medium, pre-activating VGamma9VDelta2T cells and NKT cells therein, and amplifying the VGamma9VDelta2T cells and NKT cells by selective in-vitro activation; 2) transducing the mixed cells of step 1) by using a lentiviral vector carrying chimeric antigen receptor's gene sequence. It is possible to carry out standard and batch preparation herein by using GammaDeltaT of a healthy donor; the purities of the VGamma9VDelta2T cells and NKT cells in the application can reach 60% and 30% and above respectively without purification, and therefore pre-purification can be omitted; in-vivo activation proliferation level and existence time of CAR-VGamma9VDelta2T cells and CAR-NKT cells jointly prepared by using the method can be controlled through clinical medication.

The invention discloses an in-vitro construction method for simulating a blood brain barrier through human brain microangiogenesis. The method comprises the following steps: preparing human brain microvascular endothelial cell suspension and human astrocyte suspension, and preparing fibrinogen mother liquor and thrombin mother liquor; mixing the endothelial cell suspension, the astrocyte suspension, a DMEM (Dulbecco's Modified Eagle Medium) medium, the fibrinogen mother liquor and the thrombin mother liquor, and preparing a mixed cell gel solution; injecting the mixed cell gel solution into amicro-fluidic chip, performing thermostatic incubation to gelation, adding an endothelial growth medium into the micro-fluidic chip, and constructing a 3D cell culture chip; performing continuous culture on the 3D cell culture chip, and enabling the endothelial cells and astrocyte to grow into a brain microvascular network structure, namely correspondingly producing the simulated blood brain barrier. According to the technical scheme provided by the invention, the in-vitro model of the blood brain barrier is successfully constructed, and the characteristics of the blood brain barrier are clearly and accurately reflected.

The present invention relates to a pharmaceutical composition for cell therapy of pigmentation disorders, which comprises as an active ingredient (a) melanocytes and keratinocytes, or (b) melanocytes and fibroblasts. The cell therapy composition of this invention allows for the first time to treat pigmentation disorders through cell therapy regimen. The present composition comprises as active ingredients a mixed cell preparation of melanocytes and keratinocytes or a mixed cell preparation of melanocytes and fibroblasts such that it induces very effectively pigmentation to treat diseases associated with hypopig mentation such as vitiligo.